Company intelligence / Profile preview
AGV Discovery
Montferrier-sur-Lez, Franceagv-discovery.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AGV Discovery is developing ERK inhibitors showing strong in vitro and in vivo proofs of concept for advanced cancers with MAPK pathway deregulation; ERK inhibitor program licensed to Ipsen following preclinical milestone.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Ipsen
Beyond the preview
Go deeper on AGV Discovery.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGV Discovery.